Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry
Sign Up to like & getrecommendations! Published in 2022 at "Cell Metabolism"
DOI: 10.1016/j.cmet.2022.01.008
Abstract: Coronavirus disease 2019 (COVID-19) represents a systemic disease that may cause severe metabolic complications in multiple tissues including liver, kidney, and cardiovascular system. However, the underlying mechanisms and optimal treatment remain elusive. Our study shows… read more here.
Keywords: metabolic complications; covid; imatinib methazolamide; viral entry ... See more keywords